Johnson & Johnson (J&J) said on Jan. 8 that it has struck a voluntary deal with the Trump administration to lower drug prices for U.S. patients in exchange for tariff relief.
In a statement, the pharmaceutical and medical technology company said it will participate in the TrumpRx.gov platform to allow Americans to purchase its medicines at “significantly discounted rates” and to provide Medicaid program access at prices comparable to those in other developed nations.
